Skip to main content
Erschienen in: Heart and Vessels 6/2012

01.11.2012 | Original Article

Matrix metalloprotein-9 activation under cell-to-cell interaction between endothelial cells and monocytes: possible role of hypoxia and tumor necrosis factor-α

verfasst von: Yuko Yamamoto, Tomohiro Osanai, Fumie Nishizaki, Takanori Sukekawa, Kei Izumiyama, Shigeki Sagara, Ken Okumura

Erschienen in: Heart and Vessels | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Matrix metalloproteinase (MMP)-9 plays an important role in cardiovascular events. However, the mechanisms underlying in vivo activation of MMP-9 are largely unknown. We investigated the secretion and activation of MMP-9 under a cell-to-cell interaction, and the effects of hypoxia and cytokine. Human umbilical vein endothelial cell (HUVEC) and THP-1 (human monocyte cell line) were cultured individually, or cocultured under normoxic and hypoxic conditions. In a coculture of HUVEC and THP-1, proMMP-9 secretion was increased twofold compared with individual culture of HUVEC and THP-1, whereas MMP-2 secretion was unchanged. The increase in proMMP-9 secretion was suppressed by antiadhesion molecule antibodies and mitogen-activated protein kinase inhibitors, PD98059 (MAPK/ERK kinase1 inhibitor) and SP600125 (Jun N-terminal kinase inhibitor). ProMMP-9 secretion was increased by tumor necrosis factor (TNF)-α at 50 ng/ml (P < 0.05) but was not activated under normoxic (20%) conditions. ProMMP-9 in coculture was activated under hypoxic (<1%) conditions, and was potentiated by TNF-α (both P < 0.05). To further investigate the mechanism of hypoxia-induced MMP-9 activation, heat shock protein (Hsp)90, which was suggested to be related to MMP-9 activation, was measured by Western blot analysis. The ratio of Hsp90 to glyceraldehyde-3-phosphate dehydrogenase was increased in hypoxic (<1%) coculture conditions with TNF-α (P < 0.05). Treatment with geldanamycin and 17-DMAG (Hsp90 inhibitor) suppressed the active form of MMP-9. Cell-to-cell interaction between endothelial cells and monocytes promotes proMMP-9 synthesis and secretion. Hypoxia and inflammation are suggested to play an important role in activating proMMP-9, presumably via Hsp90.
Literatur
1.
Zurück zum Zitat Bäck M, Ketelhuth DF, Agewall S (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52:410–428PubMedCrossRef Bäck M, Ketelhuth DF, Agewall S (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52:410–428PubMedCrossRef
2.
Zurück zum Zitat Kang JH, Kim JK, Park WH, Park KK, Lee TS, Magae J, Nakajima H, Kim CH, Chang YC (2007) Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages. J Cell Biochem 102:506–514PubMedCrossRef Kang JH, Kim JK, Park WH, Park KK, Lee TS, Magae J, Nakajima H, Kim CH, Chang YC (2007) Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages. J Cell Biochem 102:506–514PubMedCrossRef
3.
Zurück zum Zitat Mestas J, Ley K (2008) Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 18:228–232PubMedCrossRef Mestas J, Ley K (2008) Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 18:228–232PubMedCrossRef
4.
Zurück zum Zitat Gough PJ, Gomez IG, Wille PT, Raines EW (2006) Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 116:59–69PubMedCrossRef Gough PJ, Gomez IG, Wille PT, Raines EW (2006) Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 116:59–69PubMedCrossRef
5.
Zurück zum Zitat Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene Investigators et al (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579–1585PubMedCrossRef Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene Investigators et al (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579–1585PubMedCrossRef
6.
Zurück zum Zitat Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndromes. Cardiovasc Res 59:812–823PubMedCrossRef Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndromes. Cardiovasc Res 59:812–823PubMedCrossRef
7.
Zurück zum Zitat Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K (2001) Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141:211–217PubMedCrossRef Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K (2001) Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141:211–217PubMedCrossRef
8.
Zurück zum Zitat Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ (2007) Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 45:849–857PubMedCrossRef Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ (2007) Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 45:849–857PubMedCrossRef
9.
Zurück zum Zitat Brown DL, Hibbs MS, Kearney M, Isner JM (1997) Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am J Cardiol 79:878–882PubMedCrossRef Brown DL, Hibbs MS, Kearney M, Isner JM (1997) Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am J Cardiol 79:878–882PubMedCrossRef
10.
Zurück zum Zitat Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K (2002) Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161:185–192PubMedCrossRef Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K (2002) Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161:185–192PubMedCrossRef
11.
Zurück zum Zitat Knox JB, Sukhova GK, Whittemore AD, Libby P (1997) Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95:205–212PubMedCrossRef Knox JB, Sukhova GK, Whittemore AD, Libby P (1997) Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95:205–212PubMedCrossRef
12.
Zurück zum Zitat Worley JR, Hughes DA, Dozio N, Gavrilovic J, Sampson MJ (2007) Low density lipoprotein from patients with type 2 diabetes increases expression of monocyte matrix metalloproteinase and ADAM metalloproteinase genes. Cardiovasc Diabetol 6:21PubMedCrossRef Worley JR, Hughes DA, Dozio N, Gavrilovic J, Sampson MJ (2007) Low density lipoprotein from patients with type 2 diabetes increases expression of monocyte matrix metalloproteinase and ADAM metalloproteinase genes. Cardiovasc Diabetol 6:21PubMedCrossRef
13.
Zurück zum Zitat Businaro R, Profumo E, Tagliani A, Buttari B, Leone S, D’Amati G, Ippoliti F, Leopizzi M, D’Arcangelo D, Capoano R, Fumagalli L, Salvati B, Riganò R (2009) Heat-shock protein 90: a novel autoantigen in human carotid atherosclerosis. Atherosclerosis 207:74–83PubMedCrossRef Businaro R, Profumo E, Tagliani A, Buttari B, Leone S, D’Amati G, Ippoliti F, Leopizzi M, D’Arcangelo D, Capoano R, Fumagalli L, Salvati B, Riganò R (2009) Heat-shock protein 90: a novel autoantigen in human carotid atherosclerosis. Atherosclerosis 207:74–83PubMedCrossRef
14.
Zurück zum Zitat Kamiya T, Kwon AH, Kanemaki T, Matsui Y, Uetsuji S, Okumura T, Kamiyama Y (1998) A simplified model of hypoxic injury in primary cultured rat hepatocytes. In Vitro Cell Dev Biol Anim 34:131–137PubMedCrossRef Kamiya T, Kwon AH, Kanemaki T, Matsui Y, Uetsuji S, Okumura T, Kamiyama Y (1998) A simplified model of hypoxic injury in primary cultured rat hepatocytes. In Vitro Cell Dev Biol Anim 34:131–137PubMedCrossRef
15.
Zurück zum Zitat Abe N, Osanai T, Fujiwara T, Kameda K, Matsunaga T, Okumura K (2006) C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci 78:1021–1028PubMedCrossRef Abe N, Osanai T, Fujiwara T, Kameda K, Matsunaga T, Okumura K (2006) C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci 78:1021–1028PubMedCrossRef
16.
Zurück zum Zitat Yokota T, Osanai T, Hanada K, Kushibiki M, Abe N, Oikawa K, Tomita H, Higuma T, Yokoyama J, Hanada H, Okumura K (2010) Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. Heart Vessels 25:460–468PubMedCrossRef Yokota T, Osanai T, Hanada K, Kushibiki M, Abe N, Oikawa K, Tomita H, Higuma T, Yokoyama J, Hanada H, Okumura K (2010) Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. Heart Vessels 25:460–468PubMedCrossRef
17.
Zurück zum Zitat Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87:5578–5582PubMedCrossRef Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87:5578–5582PubMedCrossRef
18.
Zurück zum Zitat Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed
19.
20.
Zurück zum Zitat Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G (2005) A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280:9291–9296PubMedCrossRef Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G (2005) A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280:9291–9296PubMedCrossRef
21.
Zurück zum Zitat Descamps FJ, Martens E, Ballaux F, Geboes K, Opdenakker G (2004) In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive actor in streptozotocin-induced diabetes. J Pathol 204:555–561PubMedCrossRef Descamps FJ, Martens E, Ballaux F, Geboes K, Opdenakker G (2004) In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive actor in streptozotocin-induced diabetes. J Pathol 204:555–561PubMedCrossRef
22.
Zurück zum Zitat Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, Wahlström T, Salo T, Stenman UH (2001) The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 84:1363–1371PubMedCrossRef Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, Wahlström T, Salo T, Stenman UH (2001) The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 84:1363–1371PubMedCrossRef
23.
Zurück zum Zitat Cagli KE, Aras D, Topaloglu S, Geyik B, Ayaz S, Cagirci G, Kisacik HL, Korkmaz S (2010) Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty. Heart Vessels 25:131–137PubMedCrossRef Cagli KE, Aras D, Topaloglu S, Geyik B, Ayaz S, Cagirci G, Kisacik HL, Korkmaz S (2010) Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty. Heart Vessels 25:131–137PubMedCrossRef
24.
Zurück zum Zitat Frears ER, Zhang Z, Blake DR, O’Connell JP, Winyard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381:21–24PubMedCrossRef Frears ER, Zhang Z, Blake DR, O’Connell JP, Winyard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381:21–24PubMedCrossRef
25.
Zurück zum Zitat Geurts N, Martens E, Van Aelst I, Proost P, Opdenakker G, Van den Steen PE (2008) Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 47:2689–2699PubMedCrossRef Geurts N, Martens E, Van Aelst I, Proost P, Opdenakker G, Van den Steen PE (2008) Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3. Biochemistry 47:2689–2699PubMedCrossRef
26.
Zurück zum Zitat Chen B, Piel WH, Gui L, Bruford E, Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86:627–637PubMedCrossRef Chen B, Piel WH, Gui L, Bruford E, Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86:627–637PubMedCrossRef
27.
Zurück zum Zitat Tsutsumi S, Neckers L (2007) Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98:1536–1539PubMedCrossRef Tsutsumi S, Neckers L (2007) Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98:1536–1539PubMedCrossRef
28.
Zurück zum Zitat Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507–514PubMedCrossRef Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507–514PubMedCrossRef
29.
Zurück zum Zitat Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G, Luo Y (2009) The regulatory mechanism of Hsp90 alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci USA 106:21288–21293PubMedCrossRef Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G, Luo Y (2009) The regulatory mechanism of Hsp90 alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci USA 106:21288–21293PubMedCrossRef
30.
Zurück zum Zitat Stellas D, Karameris A, Patsavoudi E (2007) Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 13:1831–1838PubMedCrossRef Stellas D, Karameris A, Patsavoudi E (2007) Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 13:1831–1838PubMedCrossRef
31.
Zurück zum Zitat Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L (2008) A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27:2478–2487PubMedCrossRef Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L (2008) A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27:2478–2487PubMedCrossRef
32.
Zurück zum Zitat Stellas D, El Hamidieh A, Patsavoudi E (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11:51PubMedCrossRef Stellas D, El Hamidieh A, Patsavoudi E (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11:51PubMedCrossRef
Metadaten
Titel
Matrix metalloprotein-9 activation under cell-to-cell interaction between endothelial cells and monocytes: possible role of hypoxia and tumor necrosis factor-α
verfasst von
Yuko Yamamoto
Tomohiro Osanai
Fumie Nishizaki
Takanori Sukekawa
Kei Izumiyama
Shigeki Sagara
Ken Okumura
Publikationsdatum
01.11.2012
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 6/2012
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-011-0214-5

Weitere Artikel der Ausgabe 6/2012

Heart and Vessels 6/2012 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.